No need for a refrigerator with these vaccines

Vaccinations are the first step in providing lifesaving healthcare for a variety of deadly disease. While vaccines are common place in many countries, people residing in developing counties have little access due to the complications involved in transporting and preserving these medications. The development of a new vaccine that doesn’t need refrigeration could be the answers people need.

“What makes this vaccine special is that it’s heat-stable, so this gives a real chance to the most vulnerable children,” explained the study’s senior author, Rebecca Grais, Ph.D., a researcher at Epicentre, the research arm of Médecins Sans Frontières (Doctors Without Borders). “This is the first phase III trial that has ever been done in Niger, and it will be probably be the first vaccine that is pre-qualified [for United Nations subsidies] out of the cold chain.” The cold chain is the temperature-controlled supply chain that vaccines need so they remain at the necessary low temperature during production, storage and distribution.

Read the full story by clicking the link below:

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.